Melanoma kills over 20,000 Europeans each year, and incidence continues to rise. Despite important progress in therapy for patients, most patients with metastatic melanoma ultimately succumb to the disease. Our objective is to identify new drugs and drug-leads that can act alone or be used in combination with current available therapies to enhance drug effectiveness and/or overcome drug resistance. Our work, and the work of others, has shown that a melanocyte developmental lineage programme becomes activated during melanoma, and that this cancer requires these developmental genes for survival. We are using the zebrafish system to study melanocyte development and to understand how these pathways become misregulated in cancer. This is relevant because zebrafish develop melanomas that look, develop and progress in a very similar way human melanomas. We are screening for new drugs and drug-leads in our zebrafish system, with a view to applying these to the human cancer condition.